At a press conference at SABCS 2012, Prof Bose presents on an analysis of data from a series of studies documenting breast cancer genome sequencing has confirmed that HER2 mutations may be ideal targets for breast cancer treatment. Further, the majority of these mutations are activating mutations that drive breast cancer cell growth in tissue culture.

The conference report of this meeting is available to read for free in ecancermedicalscience.